Descartes-25 in Relapsed/Refractory Multiple Myeloma

Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05113342

Enrollment

Registered

2021-11-09

Start date

2021-11-25

Completion date

2024-11-08

Last updated

2024-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma, Relapse Multiple Myeloma

Keywords

myeloma, multiple myeloma, Relapse Refactory multiple myeloma

Brief summary

This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.

Interventions

DRUGDescartes-25

allogeneic Mesenchymal Stem Cell product.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years and older' * diagnosed with active R/RMM, who have failed 2 lines of treatment * have measurable disease

Exclusion criteria

\- Patients with active plasma cell leukemia

Design outcomes

Primary

Measure	Time frame	Description
Maximum Tolerated Dose	1 Year	Dose Level at which no more than 20% of the patients treated have shown Dose-Limiting Toxicity.

Countries

Turkey (Türkiye), United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026